Medpace Holdings, a global full-service CRO focused on small and mid-sized biopharmaceuticals, raised $161 million by offering 7 million shares at $23, the high end of the range of $20 to $23. Medpace Holdings plans to list on the Nasdaq under the symbol MEDP. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as lead managers on the deal.
